IONS · Insider Trading
Ionis Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by IONS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-19 | Shannon L. Devers | EVP, Chief Human Resources Ofc | MIXED | +1,463 | −$59.08K |
| 2026-10-19 | Eric Swayze | EVP Research | MIXED | +72 | −$2.31K |
| 2026-09-02 | C Frank Bennett | EVP, Chief Scientific Officer | J | +110 | +$5.64K |
| 2026-09-02 | Brian Birchler | EVP, Corp and Development Ops | J | +58 | +$2.98K |
| 2026-09-02 | Patrick R. O'Neil | EVP CLO & General Counsel | J | +63 | +$3.23K |
| 2026-09-02 | Brett P Monia | Chief Executive Officer | J | +98 | +$5.03K |
| 2026-07-31 | Michael R Hayden | Director | Buy | +20,000 | +$1.06M |
| 2026-07-17 | Ludwig Hantson | Director | A | +3,399 deriv. | — |
| 2026-07-17 | Peter N Reikes | Director | A | +3,399 deriv. | — |
| 2026-07-17 | Joan E Herman | Director | M | +5,220 | — |
| 2026-07-17 | Spencer R Berthelsen | Director | M | +5,220 | — |
| 2026-07-09 | Holly B. Kordasiewicz | EVP, Chief Development Officer | Sell | −362 | −$30.52K |
| 2026-07-09 | Allene M. Diaz | Director | MIXED | — | −$387.31K |
| 2026-07-09 | C Frank Bennett | EVP, Chief Scientific Officer | MIXED | −5,536 | −$1.74M |
| 2026-07-06 | Spencer R Berthelsen | Director | A | +7,670 deriv. | — |
| 2026-07-06 | Joan E Herman | Director | A | +7,670 deriv. | — |
| 2026-07-06 | Michael R Hayden | Director | A | +7,670 deriv. | — |
| 2026-07-06 | Joseph Loscalzo | Director | A | +7,670 deriv. | — |
| 2026-07-06 | Michael J. Yang | Director | A | +7,670 deriv. | — |
| 2026-07-06 | Joseph Klein III | Director | MIXED | — | −$450.39K |
| 2026-07-06 | Allene M. Diaz | Director | A | +7,670 deriv. | — |
| 2026-06-26 | Brett P Monia | Chief Executive Officer | MIXED | — | −$2.82M |
| 2026-06-26 | Eric Swayze | EVP Research | Sell | −10,602 | −$839.49K |
| 2026-06-16 | Spencer R Berthelsen | Director | MIXED | — | −$392.56K |
| 2026-06-16 | Holly B. Kordasiewicz | EVP, Chief Development Officer | MIXED | — | −$1.18M |
| 2026-06-08 | Peter N Reikes | Director | A | +10,753 deriv. | — |
| 2026-06-08 | Ludwig Hantson | Director | A | +10,753 deriv. | — |
| 2026-06-03 | Spencer R Berthelsen | Director | MIXED | — | −$410.00K |
| 2026-05-15 | Brett P Monia | Chief Executive Officer | MIXED | — | −$208.14K |
| 2026-05-06 | Joseph Loscalzo | Director | MIXED | — | −$2.03M |
| 2026-05-05 | Joseph Klein III | Director | MIXED | — | −$266.91K |
| 2026-04-30 | Joseph Baroldi | EVP, Chief Business Officer | Sell | −1,626 | −$116.73K |
| 2026-04-17 | Joseph Baroldi | EVP, Chief Business Officer | MIXED | +5,218 | −$418.95K |
| 2026-04-17 | Brian Birchler | EVP, Corp and Development Ops | MIXED | +902 | −$73.02K |
| 2026-04-17 | Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | MIXED | +7,324 | −$368.49K |
| 2026-04-17 | B Lynne Parshall | Director | Sell | −5,000 | −$381.37K |
| 2026-04-02 | Shannon L. Devers | EVP, Chief Human Resources Ofc | Sell | −6,193 | −$458.61K |
| 2026-04-02 | Joseph Klein III | Director | MIXED | — | −$805.60K |
| 2026-03-23 | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | Sell | −5,812 | −$412.49K |
| 2026-03-18 | Elizabeth L Hougen | EVP, Finance & CFO | MIXED | −50,221 | −$7.32M |
| 2026-03-11 | Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | MIXED | — | −$1.16M |
| 2026-03-11 | Brett P Monia | Chief Executive Officer | MIXED | −12,319 | −$3.07M |
| 2026-03-11 | Patrick R. O'Neil | EVP CLO & General Counsel | Sell | −10,148 | −$763.66K |
| 2026-03-05 | Joseph Baroldi | EVP, Chief Business Officer | MIXED | −4,521 | −$435.71K |
| 2026-03-05 | C Frank Bennett | EVP, Chief Scientific Officer | MIXED | −20,000 | −$3.24M |
| 2026-03-05 | Shannon L. Devers | EVP, Chief Human Resources Ofc | MIXED | — | −$873.18K |
| 2026-03-05 | Allene M. Diaz | Director | MIXED | −14,557 | −$2.75M |
| 2026-03-05 | Joseph Klein III | Director | MIXED | −5,332 | −$1.04M |
| 2026-03-05 | Joseph Loscalzo | Director | MIXED | — | −$43.55K |
| 2026-03-03 | C Frank Bennett | EVP, Chief Scientific Officer | J | +261 | +$12.75K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Elizabeth L Hougen | EVP, Finance & CFO | 254,221 | $10.21M |
| Brett P Monia | Chief Executive Officer | 242,760 | $9.75M |
| Spencer R Berthelsen | Director | 161,303 | $6.48M |
| Brian Birchler | EVP, Corp and Development Ops | 102,883 | $4.13M |
| Richard S Geary | EVP, Chief Development Officer | 77,957 | $3.13M |
| Michael R Hayden | Director | 73,298 | $2.94M |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 63,890 | $2.57M |
| C Frank Bennett | EVP, Chief Scientific Officer | 60,128 | $2.41M |
| Patrick R. O'Neil | EVP CLO & General Counsel | 59,205 | $2.38M |
| Joseph H Wender | Director | 52,035 | $2.09M |
| B Lynne Parshall | Director | 51,344 | $2.06M |
| Joan E Herman | Director | 51,306 | $2.06M |
| Joseph Baroldi | EVP, Chief Business Officer | 49,256 | $1.98M |
| Joseph Loscalzo | Director | 47,298 | $1.90M |
| Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | 28,615 | $1.15M |
| Joseph Klein III | Director | 22,633 | $908.71K |
| Eric Swayze | EVP Research | 22,202 | $891.41K |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 22,096 | $887.15K |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | 19,168 | $769.60K |
| Peter N Reikes | Director | 14,222 | $571.01K |
| Michael J. Yang | Director | 7,940 | $318.79K |
| Allene M. Diaz | Director | 3,811 | $153.01K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IONS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.